Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 17/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 5/20 | 0.48 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494744 | 0.83 | CA12 (0.49) | PTPN1PTPN22PTPRACA12CA1 | |
| SCHEMBL2892290 | 0.81 | PTPN1 (0.61) | PTPN1PTPN22 | |
| SCHEMBL2895010 | 0.79 | PTPN1 (0.51) | PTPN1PTPN22 | |
| SCHEMBL23318052 | 0.78 | PTPN1 (0.49) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL22280882 | 0.77 | CA12 (0.49) | PTPN1CA12CA1CA2CA9 | |
| SCHEMBL7048076 | 0.76 | PTPN1 (0.57) | PTPN1PTPN22 | |
| SCHEMBL19975481 | 0.76 | CA12 (0.52) | CA12CA1CA2CA9 | |
| SCHEMBL3468734 | 0.74 | CA1 (0.56) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL19667608 | 0.74 | PTPN1 (0.54) | PTPN1PTPN22CA12CA1CA2 | |
| SCHEMBL3927385 | 0.73 | PTPN1 (0.54) | PTPN1PTPN22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972340-B2 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | PTPN1 10/4885PTPN22 33/4885PTPRA 59/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | PTPN1 10/4885PTPN22 33/4885PTPRA 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.